ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 144 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $48,475,000 | +40.8% | 1,447,002 | +11.9% | 0.01% | +28.6% |
Q3 2016 | $34,423,000 | +29.9% | 1,293,604 | +7.6% | 0.01% | +16.7% |
Q2 2016 | $26,503,000 | -23.8% | 1,201,932 | +1.5% | 0.01% | -25.0% |
Q1 2016 | $34,774,000 | -8.4% | 1,184,007 | +2.9% | 0.01% | -11.1% |
Q4 2015 | $37,981,000 | -8.9% | 1,150,230 | -0.3% | 0.01% | -18.2% |
Q3 2015 | $41,711,000 | +40.4% | 1,154,139 | +74.8% | 0.01% | +57.1% |
Q2 2015 | $29,700,000 | +84.2% | 660,148 | +25.4% | 0.01% | +75.0% |
Q1 2015 | $16,125,000 | -37.4% | 526,625 | +4.0% | 0.00% | -33.3% |
Q4 2014 | $25,758,000 | +161.2% | 506,542 | +103.2% | 0.01% | +100.0% |
Q3 2014 | $9,863,000 | -10.1% | 249,249 | -2.1% | 0.00% | 0.0% |
Q2 2014 | $10,970,000 | +167.3% | 254,706 | +148.2% | 0.00% | +200.0% |
Q1 2014 | $4,104,000 | +50.8% | 102,624 | +2.9% | 0.00% | 0.0% |
Q4 2013 | $2,722,000 | +13.9% | 99,780 | -4.3% | 0.00% | 0.0% |
Q3 2013 | $2,389,000 | +46.8% | 104,228 | +13.5% | 0.00% | 0.0% |
Q2 2013 | $1,627,000 | – | 91,844 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |